1 In 4 Biotech Drugs Gets Safety Warning: Study

Law360, New York (October 21, 2008, 12:00 AM EDT) -- About one-quarter of biotechnology drugs approved in the the U.S. and European Union have been subject to safety-related regulatory actions within their first decade on the market, a new study has shown.

Most of the actions concerned immune system disorders, infections and other disorders, but none resulted in the drugs being taken off the market. The study by the Utrecht Institute for Pharmaceutical Sciences in the Netherlands appears in the new issue of the Journal of the American Medical Association.

The study looked at 174 biotechnology...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.